Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Mehta, Nehal N ^a   Li, Katherine ^b   Szapary, Philippe ^b   Krueger, James ^c   Brodmerkel, Carrie ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Inflammation; Lipid metabolism; Psoriasis

Indexed keywords

APOLIPOPROTEIN A1; LIVER X RECEPTOR ALPHA; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE LOCATION; HEART MUSCLE METABOLISM; HUMAN; HUMAN TISSUE; LIPID METABOLISM; LXR ALPHA GENE; MAJOR CLINICAL STUDY; MALE; MCP 1 GENE; MDC GENE; MICROARRAY ANALYSIS; PATHOPHYSIOLOGY; PPAR ALPHA GENE; PSORIASIS; RISK ASSESSMENT; SKIN BIOPSY;

ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHEMOTAXIS; DEMOGRAPHY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIPID METABOLISM; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PSORIASIS; SKIN;

EID: 84882373367     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-194     Document Type: Article

References (23)

1. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006, 296:1735-1741. 10.1001/jama.296.14.1735, 17032986.
2. Gelfand JM, Dommasch E, Shin DB, Azfar RS, Kurd SK, Wang X, Troxel AB. The risk of stroke in patients with psoriasis. J Invest Dermato 2009, 129:2411-2418.
3. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010, 31:1000-1006. 10.1093/eurheartj/ehp567, 2894736, 20037179.
4. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom. Br J Dermato 2010, 163:586-592.
5. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, Gelfand JM. Attributable risk estimate of severe psoriasis on major adverse cardiac events. Am J Med 2011, 124:775e1-775e6.
6. Davidovici BB, Sattar N, Jörg PCJC, Puig L, Emery P, Barker JN, van de Kerkhof P, Ståhle M, Nestle FO, Girolomoni G, Krueger JG. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid vonditions. J Invest Dermatol 2010, 130:1785-1796. 10.1038/jid.2010.103, 20445552.
7. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355. 10.1016/j.cell.2011.04.005, 3111065, 21529710.
8. Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008, 49:499-509. 10.1194/jlr.R800001-JLR200, 18182682.
9. Calkin A, Tontonoz P. LXR signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:1513-1518. 10.1161/ATVBAHA.109.191197, 2919217, 20631351.
10. Shah A, Rader DJ, Millar JS. The effect of PPAR-α agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010, 210:35-40. 10.1016/j.atherosclerosis.2009.11.010, 20005515.
11. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009, 119:1135-1145. 10.1161/CIRCULATIONAHA.108.810721, 19221221.
12. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012, 132:2552-2564. 10.1038/jid.2012.184, 3472561, 22763790.
13. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010, 362:118-128. 10.1056/NEJMoa0810652, 20071701, ACCEPT Study Group.
14. Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, Voorhees JJ, Abecasis G, Elder JT. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010, 130:1829-1840. 10.1038/jid.2010.36, 3128718, 20220767.
15. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874. 10.1038/nature01323, 12490960.
16. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008, 88:561-565.
17. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003, 107:690-695. 10.1161/01.CIR.0000049742.68848.99, 12578870.
18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695. 10.1056/NEJMra043430, 15843671.
19. Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 2011, 147:1031-1039. 10.1001/archdermatol.2011.119, 3158301, 21576552.
20. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, Derohannesian S, Wolfe M, Reilly MP, Rader DJ, VanVoorhees A, Gelfand JM. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012, 224:218-221. 10.1016/j.atherosclerosis.2012.06.068, 3693845, 22858285.
21. Shah R, Lu Y, Hinkle CC, McGillicuddy FC, Kim R, Hannenhalli S, Cappola TP, Heffron S, Wang X, Mehta NN, Putt M, Reilly MP. Gene profiling of human adipose tissue during evoked inflammation in vivo. Diabetes 2009, 58:2211-2219. 10.2337/db09-0256, 2750231, 19581417.
22. Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, Lu Y, Putt ME, Ahima RS, Reilly MP. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 2011, 60:1512-1518. 10.2337/db10-0956, 3292325, 21525510.
23. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011, 20:544-549. 10.1111/j.1600-0625.2011.01308.x, 21692858.